Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
agilon health, inc. stock logo
AGL
agilon health
$5.17
-5.3%
$5.71
$4.41
$26.75
$2.12B0.495.89 million shs4.26 million shs
Edap Tms S.A. stock logo
EDAP
Edap Tms
$7.15
-1.5%
$7.14
$3.60
$12.23
$265.27M0.7439,325 shs22,741 shs
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$0.48
$0.54
$0.40
$1.09
$577.91M-0.681.74 million shs1.50 million shs
Veru Inc. stock logo
VERU
Veru
$1.27
-3.1%
$0.77
$0.36
$1.92
$185.90M-0.222.38 million shs1.40 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
agilon health, inc. stock logo
AGL
agilon health
-5.40%+15.81%+5.62%-20.66%-79.35%
Edap Tms S.A. stock logo
EDAP
Edap Tms
-1.52%-3.77%-3.44%+14.95%-33.49%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
+0.02%-4.36%-0.61%-21.55%-3.98%
Veru Inc. stock logo
VERU
Veru
-3.05%-16.99%+126.79%+211.81%-9.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
agilon health, inc. stock logo
AGL
agilon health
1.3913 of 5 stars
4.11.00.00.01.70.00.6
Edap Tms S.A. stock logo
EDAP
Edap Tms
2.9872 of 5 stars
3.55.00.00.02.51.70.6
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
1.2635 of 5 stars
3.41.00.00.03.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
agilon health, inc. stock logo
AGL
agilon health
2.18
Hold$9.4683.24% Upside
Edap Tms S.A. stock logo
EDAP
Edap Tms
3.00
Buy$14.67105.13% Upside
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
2.75
Moderate Buy$3.33162.47% Upside

Current Analyst Ratings

Latest ONT, NWBO, EDAP, AGL, and VERU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
agilon health, inc. stock logo
AGL
agilon health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$6.00
4/15/2024
Veru Inc. stock logo
VERU
Veru
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.00
4/1/2024
Edap Tms S.A. stock logo
EDAP
Edap Tms
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $19.00
3/28/2024
Veru Inc. stock logo
VERU
Veru
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$3.00
3/6/2024
agilon health, inc. stock logo
AGL
agilon health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderweight$5.00
2/29/2024
agilon health, inc. stock logo
AGL
agilon health
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $9.00
2/29/2024
agilon health, inc. stock logo
AGL
agilon health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$10.00 ➝ $7.50
2/28/2024
agilon health, inc. stock logo
AGL
agilon health
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$7.00 ➝ $6.00
2/28/2024
agilon health, inc. stock logo
AGL
agilon health
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $8.00
2/26/2024
agilon health, inc. stock logo
AGL
agilon health
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$25.00 ➝ $6.50
2/26/2024
agilon health, inc. stock logo
AGL
agilon health
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$12.00 ➝ $6.50
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
agilon health, inc. stock logo
AGL
agilon health
$4.32B0.49N/AN/A$1.63 per share3.17
Edap Tms S.A. stock logo
EDAP
Edap Tms
$65.42M4.05N/AN/A$1.66 per share4.31
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$1.93M299.43N/AN/A($0.06) per share-8.00
Veru Inc. stock logo
VERU
Veru
$16.30M11.41N/AN/A$0.22 per share5.77

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
agilon health, inc. stock logo
AGL
agilon health
-$262.60M-$0.65N/AN/AN/A-5.76%-21.74%-8.89%5/7/2024 (Confirmed)
Edap Tms S.A. stock logo
EDAP
Edap Tms
-$22.92M-$0.63N/AN/AN/A-35.03%-34.33%-22.28%5/15/2024 (Estimated)
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
-$62.60M-$0.06N/AN/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)
Veru Inc. stock logo
VERU
Veru
-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)

Latest ONT, NWBO, EDAP, AGL, and VERU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
agilon health, inc. stock logo
AGL
agilon health
-$0.01N/A+$0.01N/AN/AN/A  
4/1/2024Q1 2024
Veru Inc. stock logo
VERU
Veru
N/A-$0.09-$0.09-$0.10N/A$2.14 million
3/27/2024Q4 2023
Edap Tms S.A. stock logo
EDAP
Edap Tms
-$0.02-$0.15-$0.13-$0.15$21.30 million$21.27 million
3/5/2024Q4 2023
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A-$0.02-$0.02-$0.02N/A$0.45 million
2/27/2024Q4 2023
agilon health, inc. stock logo
AGL
agilon health
-$0.28-$0.41-$0.13-$0.25$1.02 billion$1.06 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
agilon health, inc. stock logo
AGL
agilon health
$1.8034.85%N/AN/A N/A
Edap Tms S.A. stock logo
EDAP
Edap Tms
N/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
agilon health, inc. stock logo
AGL
agilon health
0.05
1.51
1.51
Edap Tms S.A. stock logo
EDAP
Edap Tms
0.04
2.84
2.30
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A
0.09
0.09
Veru Inc. stock logo
VERU
Veru
N/A
3.21
2.79

Ownership

Institutional Ownership

CompanyInstitutional Ownership
agilon health, inc. stock logo
AGL
agilon health
N/A
Edap Tms S.A. stock logo
EDAP
Edap Tms
62.74%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.04%
Veru Inc. stock logo
VERU
Veru
47.16%

Insider Ownership

CompanyInsider Ownership
agilon health, inc. stock logo
AGL
agilon health
3.60%
Edap Tms S.A. stock logo
EDAP
Edap Tms
0.23%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
9.40%
Veru Inc. stock logo
VERU
Veru
14.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
agilon health, inc. stock logo
AGL
agilon health
1,117409.54 million397.49 millionNot Optionable
Edap Tms S.A. stock logo
EDAP
Edap Tms
30737.10 million37.02 millionOptionable
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
251.20 billion1.04 billionNot Optionable
Veru Inc. stock logo
VERU
Veru
189146.38 million125.60 millionOptionable

ONT, NWBO, EDAP, AGL, and VERU Headlines

SourceHeadline
Netflix To Stop Sharing Subscriber Data; Stock DipsNetflix To Stop Sharing Subscriber Data; Stock Dips
markets.businessinsider.com - April 19 at 6:13 PM
What Makes Veru (VERU) a New Buy StockWhat Makes Veru (VERU) a New Buy Stock
zacks.com - April 17 at 1:01 PM
Veru (NASDAQ:VERU) Given "Outperform" Rating at OppenheimerVeru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimer
americanbankingnews.com - April 16 at 3:26 AM
Veru (NASDAQ:VERU) Earns "Outperform" Rating from OppenheimerVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimer
marketbeat.com - April 15 at 8:29 AM
REVEALED: Transport Malta officials at centre of maritime fines corruption racketREVEALED: Transport Malta officials at centre of maritime fines corruption racket
maltatoday.com.mt - April 2 at 12:43 AM
Veru Announces Date of 2024 Annual Meeting of ShareholdersVeru Announces Date of 2024 Annual Meeting of Shareholders
finance.yahoo.com - April 1 at 7:43 PM
Flag carrier Air Malta ceases operations today, its 50th birthdayFlag carrier Air Malta ceases operations today, its 50th birthday
maltatoday.com.mt - March 31 at 6:39 PM
Veru IncVeru Inc
morningstar.com - March 29 at 9:35 PM
Updated | Mosta trees vandalised: ERA, police investigatingUpdated | Mosta trees vandalised: ERA, police investigating
maltatoday.com.mt - March 29 at 8:54 AM
Raymond James Begins Coverage on Veru (NASDAQ:VERU)Raymond James Begins Coverage on Veru (NASDAQ:VERU)
marketbeat.com - March 28 at 8:28 AM
R&B Realty’s Gateway at Wynwood hit with foreclosure lawsuitR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuit
therealdeal.com - March 22 at 6:18 PM
Veru Reschedules Annual Meeting of ShareholdersVeru Reschedules Annual Meeting of Shareholders
globenewswire.com - March 22 at 4:05 PM
Wynwood offices targeted in $102M foreclosureWynwood offices targeted in $102M foreclosure
bizjournals.com - March 21 at 6:43 PM
Naksha Saran plays a bike taxi driver in her next filmNaksha Saran plays a bike taxi driver in her next film
msn.com - March 19 at 4:27 AM
Precise and efficient cutting (sawing) of lightweight core materialsPrecise and efficient cutting (sawing) of lightweight core materials
jeccomposites.com - March 18 at 1:24 PM
VERU Mar 2024 0.500 putVERU Mar 2024 0.500 put
ca.finance.yahoo.com - March 16 at 1:30 PM
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight LossVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
globenewswire.com - March 12 at 8:00 AM
VERU Mar 2024 1.500 putVERU Mar 2024 1.500 put
finance.yahoo.com - March 11 at 11:33 PM
Brussels is mixed bag of emotions on possible Joseph Muscat returnBrussels is mixed bag of emotions on possible Joseph Muscat return
maltatoday.com.mt - March 11 at 1:32 PM
VERU Jan 2025 17.000 callVERU Jan 2025 17.000 call
finance.yahoo.com - March 9 at 6:52 PM
VERU Mar 2024 0.500 callVERU Mar 2024 0.500 call
finance.yahoo.com - March 9 at 1:52 PM
VERU Mar 2024 3.000 putVERU Mar 2024 3.000 put
finance.yahoo.com - March 9 at 1:52 PM
VERU Mar 2024 2.500 putVERU Mar 2024 2.500 put
finance.yahoo.com - March 1 at 11:31 PM
Veru gets Nasdaq notice related to delayed quarterly report on form 10-QVeru gets Nasdaq notice related to delayed quarterly report on form 10-Q
msn.com - February 28 at 11:04 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

agilon health logo

agilon health

NYSE:AGL
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Edap Tms logo

Edap Tms

NASDAQ:EDAP
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.
Northwest Biotherapeutics logo

Northwest Biotherapeutics

OTCMKTS:NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Veru logo

Veru

NASDAQ:VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.